Masaoka T, Kageyama T, Tatsumi N, Akasaka K, Yonezawa T, Sugiyama H, Kitani T, Yasunaga K, Horiuchi A, Nakayama S
5th Dept. of Internal Medicine, Center for Adult Diseases, Osaka.
Gan To Kagaku Ryoho. 1992 Mar;19(3):339-47.
A late phase II study with MST-16 for malignant lymphoma was performed with the collaboration of 11 institutions belonging to the Hanshin Hematological Disease Treatment Research Group. Out of a total 40 patients entered into the study, 37 cases (33 of NHL and 4 HD) were evaluated for efficacy and 27 cases for side effects. The response rate was 29.7% (2 cases of CR and 9 PR). The factors affecting response rate were histological classification, phenotype of tumor cell surface and stage of disease. Bone marrow suppression and G-I disorders were the main toxicities observed, but they disappeared by the cessation of MST-16 treatment.
一项针对恶性淋巴瘤的MST - 16 II期晚期研究是在阪神血液疾病治疗研究小组所属的11家机构合作下进行的。在总共40名进入该研究的患者中，37例（33例非霍奇金淋巴瘤和4例霍奇金病）接受了疗效评估，27例接受了副作用评估。缓解率为29.7%（2例完全缓解和9例部分缓解）。影响缓解率的因素有组织学分类、肿瘤细胞表面表型和疾病分期。观察到的主要毒性反应是骨髓抑制和胃肠道紊乱，但在停止MST - 16治疗后它们消失了。
